### PATENT COOPERATION TREATY

### PCT

REC'D 10 JAN 2005

## INTERNATIONAL PRELIMINARY REPORT ON PATEMINABILITYCE

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR 51125115		
70221	FOR FURTHER A	CTION	See Form PCT/IPEA/416
International application No. PCT/EP2004/000972	international filing date 03.02.2004	(day/month/year)	Priority date (day/month/year) 04.02.2003
International Patent Classification (IPC) or I	national classification and	IPC	
C07H17/08, A61K31/70, A61P33/0	0		
Applicant			
SYNGENTA PARTICIPATIONS AG	G		
This report is the international pro-	oliminany avamination		
Authority under Article 35 and tra	insmitted to the applica	eport, established by tr nt according to Article 3	nis International Preliminary Examining 36.
2. This REPORT consists of a total	of 5 sheets, including t	his cover sheet.	
3. This report is also accompanied			
a. D sent to the applicant and t	to the International Bure	eau) a total of sheets,	as follows:
□ sheets of the descript and/or sheets contain Administrative Instruc	ing recuircations author	ngs which have been a zed by this Authority (s	amended and are the basis of this report see Rule 70.16 and Section 607 of the
☐ sheets which superse beyond the disclosure Supplemental Box.	ede earlier sheets, but we in the international app	hich this Authority consolication as filed, as ind	siders contain an amendment that goes licated in item 4 of Box No. I and the
b. (sent to the International F	Bureau only) a total of (i	ndicate type and numb	
Box Relating to Sequence	Listing (see Section 80	2 of the Administrative	Instructions).
	·		
4. This report contains indications re	elating to the following it	ems:	
☐ Box No. I Basis of the opi	inion		
☐ Box No. II Priority			
☑ Box No. III Non-establishm	ent of opinion with rega	rd to novelty, inventive	step and industrial applicability
☐ Box No. IV Lack of unity of	invention		
applicability, cit	ations and explanations	2) with regard to novelty supporting such states	y, inventive step or industrial ment
☐ Box No. VI Certain docume			
	in the international app		
☐ Box No. VIII Certain observa	tions on the internation	al application	
Date of submission of the demand		Date of completion of th	als report
		,	
22.07.2004		07.01.2005	
Name and mailing address of the internation preliminary examining authority:	al .	Authorized Officer	
European Patent Office		. •	Septimona Patentes.
D-80298 Munich Tel. +49 89 2399 - 0 Tx: 5236	56 epmu d	Bardili, W	
Fax: +49 89 2399 - 4465		Telephone No. +49 89 2	2399-2132

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/000972

_	Во	x No. I	Basis of the repor	t.	
1.	. With regard to the <b>language</b> , this report is based on the international application in the language in which it v filed, unless otherwise indicated under this item.				
		This re	nslations from the original language into the following language , translation furnished for the purposes of:		
		□ pub	dication of the interna	der Rules 12.3 and 23.1(b)) ational application (under Rule 12.4) v examination (under Rules 55.2 and/or 55.3)	
2.	With regard to the elements* of the international application, this report is based on (replacement sheets who have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):				
	Des	cription	, Pages		
	1-68	3		as originally filed	
Claims, Numbers					
	1-8			as originally filed	
		a sequ	ence listing and/or ar	ny related table(s) - see Supplemental Box Relating to Sequence Listing	
3.		The an	nendments have resi	ulted in the cancellation of:	
		☐ the	description, pages claims, Nos.		a.
		☐ the	drawings, sheets/figs sequence listing (spe	3	
		□ any	table(s) related to se	ecity): equence listing (specify): .	
4.	Sup	plemen	tal Box (Rule 70.2(c)	ished as if (some of) the amendments annexed to this report and listed be have been considered to go beyond the disclosure as filed, as indicated i).	elow n the
		☐ the	description, pages claims, Nos.		
		☐ the	drawings, sheets/figs	<b>;</b>	
		☐ the	sequence listing (spe	ecify): equence listing <i>(specify)</i> :	
	*	If ite	em 4 applies, so	ome or all of these sheets may be marked "superseded."	

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/000972

		x No. III Non-establishment o Dicability	of op	inion with regard to novelty, inventive step and industrial		
1.	The	ne questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- ovious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
		claims Nos. 3,6 with respect to industrial applicability				
		because:				
	☒	the said international application, or the said claims Nos. 3,6 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleo not comply with the technical re	tide a equire	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
		See separate sheet for further	detai	ls ·		

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/000972

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1-8

1. Statement

Novelty (N) Yes: Claims

No: Claims

Inventive step (IS) Yes: Claims 1-8

No: Claims

Industrial applicability (IA) Yes: Claims 1,2,4,5,7,8

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/000972

#### Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 3 and 6 encompass medical treatment of the animal body (see page 17 of the description) and relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

#### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Avermectin derivatives modified at 4" or 4' by substituted amino or hydroxy radicals are known, for instance from WO-A-02 068 442 or J. Agric. Food Chem. 42, 1786-90 (1994). The claimed avermectin derivatives are novel compounds owing to the 4" (4') substituent  $-O-N(R_2)R_3$ .

The object of the invention can be seen in the provision of new pesticides. The application contains data demonstrating that the claimed compounds have the alleged pesticidal activity. Since the biological activity of the new pesticides was not derivable from the state of the art inventive step is acknowledged.

2. For the assessment of the present claims 3 and 6 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.